Skip to main content
Explore URMC

menu

Essential Thrombocythemia: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Research Question:
What is the safety, tolerability and effectiveness of ruxolitinib compared to anagrelide in patients with Essential Thrombocythemia who are resistant or intolerant to hydroxyurea?

Basic Study Information

Purpose:
This study has two groups. The first group, Group A, will be treated with ruxolitinib and placebo and the second group, Group B, will be treated with anagrelide and placebo. You will be randomly assigned (like flipping a coin) to Group A or Group B. Neither you nor your Study Doctor can identify which group you will be assigned to. You will have equal chance of receiving ruxolitinib or anagrelide.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03123588?term=INCB+18424-272&rank=1 https://clinicaltrials.gov/ct2/show/NCT03123588?term=INCB+18424-272&draw=1&rank=1
Study Reference #: IHEM17035

Lead Researcher (Principal Investigator)

Lead Researcher: Frank Akwaa

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Email: Brandon_Delorme@URMC.Rochester.edu

Additional Study Details

Return to Search